Zhang, Xingyi
Lu, Jiapeng
Wu, Chaoqun
Cui, Jianlan
Wu, Yue
Hu, Anyi
Li, Jing
Funding for this research was provided by:
CAMS Innovation Fund for Medical Science (2021-1-I2M-011)
National Key Research and Development Program from the Ministry of Science and Technology of China (2017YFC1310800, 2017YFC1310803)
Ministry of Finance of China and National Health Commission of China
111 Project from the Ministry of Education of China (B16005)
Article History
Received: 6 April 2021
Accepted: 29 November 2021
First Online: 18 December 2021
Declarations
:
: The project protocol was approved by the central ethics committee at Fuwai Hospital, Beijing, China (Approval No. 2014–574). Written informed consent was obtained from all enrolled participants.
: Not applicable.
: Dr. Jing Li reported receiving research grants, through Fuwai Hospital, from the People’s Republic of China for work to improve the management of hypertension and blood lipids and to improve care quality and patient outcomes of cardiovascular disease; receiving research agreements, through the National Center for Cardiovascular Diseases and Fuwai Hospital, from Amgen for a multicentre clinical trial assessing the efficacy and safety of omecamtiv mecarbil and for dyslipidaemia patient registration; receiving a research agreement, through Fuwai Hospital, from Sanofi for a multicentre clinical trial on the effects of sotagliflozin; receiving a research agreement, through Fuwai Hospital, with the University of Oxford for a multicentre clinical trial of empagliflozin; receiving a research agreement, through the National Center for Cardiovascular Diseases, from AstraZeneca for clinical research methods training outside the submitted work; and receiving a research agreement, through the National Center for Cardiovascular Diseases, from Lilly for physician training outside the submitted work. No other disclosures were reported.